A Multi-cohort, Open-label, Multi-center Exploratory Study of Efbemalenograstim Alfa Injection for Preventing Absolute Neutrophil Count (ANC) Reduction in Solid Tumor Patients Undergoing Immune-chemotherapy Regimen.
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Efbemalenograstim alfa (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- 23 Oct 2024 New trial record